Skip Navigation



European Heart Journal Advance Access published online on May 13, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn192
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
29/15/1873    most recent
ehn192v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Gillis, A. M.
Right arrow Articles by George Wyse, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gillis, A. M.
Right arrow Articles by George Wyse, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation

Anne M. Gillis*, Margaret Morck, Derek V. Exner, Andrea Soo, M. Sarah Rose, Robert S. Sheldon, Henry J. Duff, Katherine M. Kavanagh, L. Brent Mitchell and D. George Wyse

Libin Cardiovascular Institute of Alberta and Department of Cardiac Sciences, University of Calgary and Calgary Health Region, HSC Room 1634, 3330 Hospital Drive NW, Calgary, AB, Canada T2N 4N1

Received 23 May 2007; revised 8 April 2008; accepted 17 April 2008.

* Corresponding author. Tel: +1 403 220 6841, Fax: +1 403 270 0313, Email: amgillis{at}ucalgary.ca

Aims: Data suggest that atrial pacing, statins, angiotensin-converting enzyme-inhibitors and angiotensin receptor blocking drugs prevent atrial tachycardia/atrial fibrillation (AT/AF) in some patients. The clinical predictors of AT/AF recurrence following dual-chamber pacemaker insertion were examined in 185 consecutive patients with paroxysmal AF.

Methods and results: Predictors of AT/AF recurrence were evaluated in this observational cohort study. The time to first AT/AF recurrence and AT/AF burden (h/day) was retrieved at each follow-up visit by interrogating the pacemaker. AT/AF recurred following pacemaker implantation in 157 (85%) patients. At 1 year of follow-up, patients without recurrence were more likely to be on statin therapy (54%) when compared with patients without statin therapy (25%, {chi} = 12.31, P = 0.0004). Statin therapy was the only significant predictor of AT/AF recurrence in a multivariate logistic regression model (adjusted odds ratio 0.33, 95% confidence interval 0.14–0.74, P = 0.007). AT/AF burden was significantly lower in the group on statin therapy (median 0.10 h/day) when compared with the group not on statin therapy (median 0.39 h/day, P = 0.0059).

Conclusion: AT/AF recurs frequently following pacemaker implantation in patients with sinus node disease. The progression to permanent AF remains low over time. Statin therapy was significantly associated with AT/AF suppression.

Key Words: Atrial fibrillation • Dual-chamber pacing • Statins


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
C. W. Israel
Effect of statins in 'upstream therapy' of atrial fibrillation: better reliability with implantable cardiac monitors
Eur. Heart J., August 1, 2008; 29(15): 1798 - 1799.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.